Taken together, current data support a treat-to-target strategy that acknowledges attenuated healing rates in the proximal small bowel, positions anti-TNF agents as the most substantiated class for UGI-CD, and recognizes the modest benefit of other biologics or small molecules. Here, TNF is linked to Cowden disease.